Future proofing the life sciences supply chain will require redefining the supply chain to become more agile, increasing capabilities to support demand-driven performance, and aligning value to unleash untapped assets and expertise.
This report provides a clear indication about the demands of future proofing the supply chain. Planned and executed properly, the process requires a high degree of commitment, discipline and buy-in from stakeholders.
The report also notes that the benefits of future proofing are being demonstrated every day in global pharmaceutical markets, enabling increased revenue growth, optimised new product pipelines, improved material flows and reduced operational risk.
The three drivers to redefine the supply chain outlined in the report are:
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm. All rights reserved.